Cell Therapy Manufacturing: Market Size & Forecast 2026

The global cell therapy manufacturing market reached approximately USD 25.6 billion in 2025, anchored by the near-term commercialisation of autologous CAR-T therapies and the expanding clinical pipeline across oncology, autoimmune, and rare disease indications. The market is structurally tight: demand is accelerating as approved indications broaden beyond haematological malignancies, while manufacturing capacity remains constrained by the specialised GMP infrastructure, skilled workforce requirements, and complex supply chains that characterise living-product manufacturing. Capacity utilisation sits at roughly 72-78% across North American and European facilities, leaving limited headroom to absorb pipeline growth without new capital deployment [Claight estimate: derived from facility count x annual batch throughput benchmarks]. > **Analyst Take.** The call on this category is not whether

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.